Relmada Therapeutics Relocates Principal Offices
Ticker: RLMD · Form: 8-K · Filed: Sep 10, 2025 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, administrative
TL;DR
Relmada Therapeutics moved its main office to Coral Gables, FL.
AI Summary
On September 10, 2025, Relmada Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134. The company's former name was Camp Nine, Inc., which was changed on July 6, 2012.
Why It Matters
This filing signals a change in the company's operational base, which could impact logistics, employee location, and potentially investor relations depending on the reasons for the move.
Risk Assessment
Risk Level: low — The filing is a routine administrative update regarding office location and does not contain information about financial performance or significant business events.
Key Players & Entities
- Relmada Therapeutics, Inc. (company) — Registrant
- Camp Nine, Inc. (company) — Former company name
- September 10, 2025 (date) — Date of earliest event reported
- 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134 (location) — New principal executive offices address
- July 6, 2012 (date) — Date of former company name change
FAQ
What is the new address for Relmada Therapeutics, Inc.'s principal executive offices?
The new address is 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 10, 2025.
What was Relmada Therapeutics, Inc.'s former company name?
The former company name was Camp Nine, Inc.
On what date did the company change its name from Camp Nine, Inc.?
The date of the name change was July 6, 2012.
In which state is Relmada Therapeutics, Inc. incorporated?
Relmada Therapeutics, Inc. is incorporated in Nevada.
Filing Stats: 569 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-09-10 08:46:05
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The NASDAQ
Filing Documents
- ea0256582-8k_relmada.htm (8-K) — 29KB
- ea025658201ex99-1_relmada.htm (EX-99.1) — 21KB
- ea025658201ex99-2_relmada.htm (EX-99.2) — 47KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- ex99-2_001.jpg (GRAPHIC) — 191KB
- ex99-2_002.jpg (GRAPHIC) — 297KB
- ex99-2_003.jpg (GRAPHIC) — 209KB
- ex99-2_004.jpg (GRAPHIC) — 223KB
- ex99-2_005.jpg (GRAPHIC) — 87KB
- ex99-2_006.jpg (GRAPHIC) — 242KB
- ex99-2_007.jpg (GRAPHIC) — 250KB
- ex99-2_008.jpg (GRAPHIC) — 194KB
- ex99-2_009.jpg (GRAPHIC) — 195KB
- ex99-2_010.jpg (GRAPHIC) — 173KB
- ex99-2_011.jpg (GRAPHIC) — 279KB
- ex99-2_012.jpg (GRAPHIC) — 219KB
- ex99-2_013.jpg (GRAPHIC) — 230KB
- ex99-2_014.jpg (GRAPHIC) — 96KB
- ex99-2_015.jpg (GRAPHIC) — 168KB
- ex99-2_016.jpg (GRAPHIC) — 134KB
- ex99-2_017.jpg (GRAPHIC) — 120KB
- ex99-2_018.jpg (GRAPHIC) — 109KB
- ex99-2_019.jpg (GRAPHIC) — 172KB
- ex99-2_020.jpg (GRAPHIC) — 163KB
- ex99-2_021.jpg (GRAPHIC) — 202KB
- ex99-2_022.jpg (GRAPHIC) — 210KB
- ex99-2_023.jpg (GRAPHIC) — 155KB
- ex99-2_024.jpg (GRAPHIC) — 71KB
- ex99-2_025.jpg (GRAPHIC) — 174KB
- ex99-2_026.jpg (GRAPHIC) — 216KB
- ex99-2_027.jpg (GRAPHIC) — 137KB
- ex99-2_028.jpg (GRAPHIC) — 261KB
- ex99-2_029.jpg (GRAPHIC) — 189KB
- ex99-2_030.jpg (GRAPHIC) — 148KB
- ex99-2_031.jpg (GRAPHIC) — 37KB
- ex99-2_032.jpg (GRAPHIC) — 117KB
- ex99-2_033.jpg (GRAPHIC) — 137KB
- ex99-2_034.jpg (GRAPHIC) — 40KB
- ex99-2_035.jpg (GRAPHIC) — 32KB
- ex99-2_036.jpg (GRAPHIC) — 152KB
- 0001213900-25-086389.txt ( ) — 8593KB
- rlmd-20250910.xsd (EX-101.SCH) — 3KB
- rlmd-20250910_lab.xml (EX-101.LAB) — 33KB
- rlmd-20250910_pre.xml (EX-101.PRE) — 22KB
- ea0256582-8k_relmada_htm.xml (XML) — 4KB
01 Regulation
Item 7.01 Regulation FD Disclosure. On September 10, 2025, Relmada Therapeutics, Inc. (the "Company") issued a letter to its shareholders providing an update on the Company's recent progress, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this
01 by reference
Item 7.01 by reference. On September 10, 2025, the Company also updated its corporate presentation, a copy of which is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial
Item 9.01. Financial (d) Exhibits Exhibit No. Description 99.1* Letter to Shareholders dated September 10, 2025 99.2* Corporate Presentation dated September 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 10, 2025 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 2